跳至主要内容
临床试验/NCT00165867
NCT00165867已完成2 期

An Open Label Phase II Study of Indisulam in Combination With Irinotecan in Patients With Metastatic Colorectal Cancer Who Have Been Previously Treated With 5-Fluorouracil/Leucovorin and Oxaliplatin

Eisai Limited14 个研究点 分布在 2 个国家目标入组 40 人开始时间: 2005年4月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Eisai Limited
入组人数
40
试验地点
14
主要终点
The objective response rate as defined by RECIST criteria.

研究概览

简要总结

The overall purpose of this study is to determine the efficacy, safety and tolerability of indisulam in combination with irinotecan as a treatment for patients with metastatic colorectalcancer previously treated with 5-fluorouracil/leucovorin and oxaliplatin (FOLFOX).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The objective response rate as defined by RECIST criteria.

次要结局

  • Duration of response
  • time to progression
  • overall survival
  • safety and tolerability of the combination

研究者

发起方
Eisai Limited
申办方类型
Industry

研究点 (14)

Loading locations...

相似试验